Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. Biocartis Group NV
  6. News
  7. Summary
    BCART   BE0974281132

BIOCARTIS GROUP NV

(BCART)
  Report
Real-time Quote. Real-time Euronext Bruxelles - 09/17 06:25:07 am
3.845 EUR   +2.95%
09/13BIOCARTIS : Disclosure of a transparency notification
PU
09/13PRESS RELEASE BIOCARTIS GROUP NV : Disclosure of a transparency notification
AQ
09/02BIOCARTIS : Webcast presentation H1 2021 results
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

GeneproDX announced that it has received $3.2 million in funding from Biocartis Group NV and other investors

06/22/2021 EDT

GeneproDX announced that it has received $3,200,000 in a round of funding led by new investor, Biocartis Group NV (ENXTBR:BCART) for $1,400,000 on June 22, 2021. The transaction also included participation from existing shareholders. The company has issued a convertible note in the transaction. The convertible note is convertible into shares of the company which will give Biocartis Group NV (ENXTBR:BCART), a stake of 5% in the company.


© S&P Capital IQ 2021
All news about BIOCARTIS GROUP NV
09/13BIOCARTIS : Disclosure of a transparency notification
PU
09/13PRESS RELEASE BIOCARTIS GROUP NV : Disclosure of a transparency notification
AQ
09/02BIOCARTIS : Webcast presentation H1 2021 results
PU
09/02BIOCARTIS : Launches Idylla™ SARS-CoV-2/Flu/RSV Panel
PU
09/02BIOCARTIS : announces H1 2021 results
PU
09/02PRESS RELEASE BIOCARTIS GROUP NV : Biocartis announces H1 2021 results
AQ
09/02Biocartis Group Nv Reports Earnings Results for the Half Year Ended June 30, ..
CI
09/02PRESS NEWS BIOCARTIS GROUP NV : Biocartis Launches Idylla™ SARS-CoV-2/Flu/..
AQ
09/02Biocartis Group NV Launches Idylla™ SARS-CoV-2/Flu/RSV Panel
CI
08/30BIOCARTIS : Disclosure of a transparency notification
PU
More news
Financials
Sales 2021 52,9 M 62,3 M 62,3 M
Net income 2021 -81,0 M -95,4 M -95,4 M
Net Debt 2021 106 M 125 M 125 M
P/E ratio 2021 -2,81x
Yield 2021 -
Capitalization 215 M 253 M 253 M
EV / Sales 2021 6,07x
EV / Sales 2022 5,07x
Nbr of Employees 484
Free-Float 86,4%
Chart BIOCARTIS GROUP NV
Duration : Period :
Biocartis Group NV Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOCARTIS GROUP NV
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 3,74 €
Average target price 6,50 €
Spread / Average Target 74,0%
EPS Revisions
Managers and Directors
Herman Verrelst Chief Executive Officer & Executive Director
Jean-Marc Roelandt Chief Financial Officer
Christian Reinaudo Independent Chairman
Benoit Devogelaere Chief Technology Officer
Piet Houwen Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
BIOCARTIS GROUP NV-19.68%253
MASIMO CORPORATION2.08%15 083
NOVOCURE LIMITED-26.55%13 143
GETINGE AB88.03%11 394
PENUMBRA, INC.66.42%10 654
ASAHI INTECC CO., LTD.-12.35%8 153